Sofinnova Ventures
-
Merck paying $2.75B for cancer therapeutics firm VelosBio
The deal will broaden Merck’s oncology portfolio as it picks up an antibody-drug conjugate, a class of biological drugs that target tumor cells even as the pharma giant jettisons other parts of its business
-
How Covid-19 has affected investment in life science startups
Amid the deepest economic crisis since the Great Depression, it has been reported that startups overall face an “existential threat.” But while life science startups have slimmer pickings than before, they stand to benefit from the industry’s more conservative investment approach.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
XyloCor closes $17M Series A round to develop gene therapy for refractory angina
The Philadelphia-based company has an IND open with the FDA and plans to begin its clinical trial in the first half of next year.
-
Galera Therapeutics raises $150M Series C round to fund clinical development
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
-
Sofinnova Ventures has raised $595M for its largest fund to date
A previous fund, dating back to 2014, raised $500 million.
-
Health IT, Devices & Diagnostics
HealthQuest raising new $175M medtech fund
A spinoff of Sofinnova Ventures, Healthquest Partners focuses more on diagnostics, medical devices and health IT startups.
-
Sofinnova appears to be bulking up a healthcare venture fund to $110 million
Looks like Sofinnova Ventures is bulking up one of its venture funds – up from […]